聖諾醫藥-B(02257.HK)啟動通過系統給藥治療實體瘤的RNAi療法STP707的I期臨牀試驗
格隆匯2月9日丨聖諾醫藥-B(02257.HK)宣佈,一項I期臨牀試驗已於美國啟動,以評估小干擾核糖核酸(siRNA)候選藥物STP707通過靜脈全身給藥治療多種實體瘤的效果。目前已有兩名患者接受了治療。
Sirnaomics創始人、董事會主席、執行董事、總裁兼首席執行官陸陽博士指出:“Sirnaomics一直在不懈推進新型核酸干擾藥物的研發創制,而STP707首次通過靜脈給藥治療肝細胞癌和其他類型的實體瘤,為本集團多年藥物研發工作的一項重要里程碑。該候選藥物在我們的臨牀前研究表現良好療效和安全性。我們的目標是利用全球獨有的多肽納米導入系統(PNP)優化siRNA藥物製劑,將其應用於現未滿足的臨牀需求,尤其是在腫瘤和纖維化疾病領域。我們有志於引領核酸干擾藥物行業開發新型腫瘤療法,而本項臨牀試驗的啟動有利地推動了本集團實現該目標。”
Sirnaomics執行董事兼首席醫療官Michael Molyneaux博士表示:“Sirnaomics的使命是運用RNAi療法來開發候選藥物,其中就包括能夠解決各種癌症患者關鍵需求的STP707。隨着這次臨牀I期試驗的啟動,我們可以通過靜脈給藥的方式擴大候選藥物的治療範圍。這意味着我們能有更多的機會來探索STP707的作用,包括我們在以前的研究中已經驗證的劑量範圍和抗腫瘤活性。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.